NEW YORK (GenomeWeb News) – GenMark Diagnostics said after the close of the market on Wednesday that revenues for its second quarter increased 44 percent year over year with strong growth in reagent and instrument revenues.

For the three months ended June 30, total revenues rose to $5.2 million from $3.6 million and beat the average Wall Street estimate of $5.1 million. The increase, GenMark said, "reflects an increase in the number of systems placed at customer sites, growth in test menus, and an increase in the number of tests sold."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.